v3.21.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Product sales, net $ 5,437,236 $ 8,374,501
Cost of products sold 1,815,924 2,656,142
Gross profit 3,621,312 5,718,359
Selling, general and administrative expenses 10,766,580 9,527,429
Research and development expenses 307,850 189,923
Total operating expenses 11,074,430 9,717,352
Loss from operations (7,453,118) (3,998,993)
Other expenses (24,790) (10,408)
Interest income 6,709 1,543
Change in fair value of derivative liability (3,635,580)
Loss before provision for income taxes and net of equity investments (7,471,199) (7,643,438)
Provision for income taxes (15,500) (18,126)
Loss before equity in net earnings of equity investments (7,486,699) (7,661,564)
Earnings from equity method investment 97,887 81,324
Net loss (7,388,812) (7,580,240)
Net loss attributable to noncontrolling interests 51,539 55,872
Net loss attributable to Milestone Scientific Inc. $ (7,337,273) $ (7,524,368)
Net loss per share applicable to common stockholders—    
Basic (in dollars per share) $ (0.12) $ (0.16)
Diluted (in dollars per share) $ (0.12) $ (0.16)
Weighted average shares outstanding and to be issued—    
Basic (in shares) 63,061,358 45,740,050
Diluted (in shares) 63,061,358 45,740,050

Source